Palatin Technologies

Palatin Technologies is a biopharmaceutical company developing first-in-class medicines that modulate the melanocortin receptor (MCR) system, focused on rare and complex obesity, ocular, and inflammatory conditions. Its MC4R-based obesity franchise includes oral small-molecule PL7737 and once-weekly long-acting peptide MC4R agonists targeting hypothalamic obesity and Prader-Willi syndrome, plus a Phase 2 combination of bremelanotide with tirzepatide. Additional programs include PL9643 for dry eye disease and oral PL8177 for inflammatory bowel disease. The company up-listed to Nasdaq in May 2026 after a 2025 restructuring, and its Boehringer Ingelheim collaboration provides non-dilutive funding and milestones.